Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Gene expression linked to survival differs by kidney cancer subtype (opens in a new tab)

medicalxpress.com · 2026-10-07

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Three of four claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 3 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredIn the overall ccRCC cohort, the hazard ratio for overall survival in the high-expression group was 2.16 compared with the low-expression group, and in stage III ccRCC high CTDNEP1 expression was significantly associated with poorer overall survival, disease-specific survival and progression-free interval.View evidenceHide evidence

As statedhazard ratio 2.16 for overall survival; stage III subgroup associations

Why this verdict

The abstract-level profile supports a poorer-prognosis association in KIRC and a notable Stage III association, but it explicitly lacks hazard ratios, confidence intervals, p-values, event counts, and detailed endpoint-specific results. The stated HR of 2.16 and the specific Stage III associations for overall survival, disease-specific survival, and progression-free interval are therefore not verifiable from the abstract-depth evidence supplied.

1

Study evidence

CTDNEP1 expression is higher in KIRC and KIRP tumor tissues than in normal kidney tissues, especially in early-stage tumors.

“Kaplan-Meier survival and Cox proportional hazard analyses were performed to evaluate the association between CTDNEP1 expression and patient prognosis.”
Claim 2 of 4SupportedResearchers at Tokyo University of Science and Nippon Medical School analyzed public cancer databases and found that high expression of CTD nuclear envelope phosphatase 1 (CTDNEP1) is associated with poorer survival outcomes in patients with clear cell renal cell carcinoma (ccRCC).View evidenceHide evidence

Why this verdict

The abstract-level profile supports that TCGA/Pan-Cancer public data were used for prognostic analysis and that high CTDNEP1 expression was associated with poorer prognosis in KIRC, which corresponds to clear cell RCC/ccRCC. The profile supports the association framing, though it does not independently verify the named institutional affiliations.

1

Study evidence

CTDNEP1 expression is higher in KIRC and KIRP tumor tissues than in normal kidney tissues, especially in early-stage tumors.

“Kaplan-Meier survival and Cox proportional hazard analyses were performed to evaluate the association between CTDNEP1 expression and patient prognosis.”
Claim 3 of 4SupportedIn papillary RCC, the association between CTDNEP1 expression and prognosis was limited and inconsistent, with no consistent association for overall survival, disease-specific survival or progression-free interval.View evidenceHide evidence

Why this verdict

The paper profile states that prognostic impact in KIRP/papillary RCC was limited and inconsistent. The claim’s endpoint-specific phrasing is more detailed than the abstract profile, but the core story framing—that KIRP findings were not consistently prognostic—is supported.

1

Study evidence

CTDNEP1 expression is higher in KIRC and KIRP tumor tissues than in normal kidney tissues, especially in early-stage tumors.

“Kaplan-Meier survival and Cox proportional hazard analyses were performed to evaluate the association between CTDNEP1 expression and patient prognosis.”
Claim 4 of 4SupportedThe researchers say CTDNEP1 could be a candidate prognostic biomarker, particularly in ccRCC, but note that the findings show association rather than direct cause-and-effect and require further experimental and clinical validation.View evidenceHide evidence

Why this verdict

The profile supports the authors’ interpretation that CTDNEP1 may have prognostic biomarker relevance, especially in KIRC/ccRCC, while emphasizing that the analyses are observational/in-silico and require further experimental and validation work. The story’s caveated, speculative framing matches the paper profile.

1

Study evidence

CTDNEP1 expression is higher in KIRC and KIRP tumor tissues than in normal kidney tissues, especially in early-stage tumors.

“Kaplan-Meier survival and Cox proportional hazard analyses were performed to evaluate the association between CTDNEP1 expression and patient prognosis.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • CTDNEP1 expression was reported as higher in KIRC and KIRP tumor tissue than in normal tissue, especially in early-stage tumors.

    The supplied story presentation focuses on prognostic survival associations and does not report the tumor-versus-normal expression finding or the early-stage expression pattern.

    From TCGA/Pan-Cancer in-silico expression comparison

  • The paper included GO/KEGG functional enrichment analyses, reporting immune-related pathway associations in KIRC and PI3K-Akt, MAPK, and TGF-beta pathway associations in KIRP.

    The supplied story presentation does not mention the functional enrichment or pathway-analysis component.

    From In-silico GO/KEGG enrichment of CTDNEP1-associated gene sets

  • The paper included immune infiltration analysis and reported only weak correlations between CTDNEP1 expression and immune cell infiltration.

    The story presentation does not mention the immune infiltration analysis or its weak-correlation result.

    From in_silico

5 things the story did carry across
  • The paper analyzed CTDNEP1 expression in RCC subtypes using TCGA/Pan-Cancer Atlas data, including KIRC and KIRP.
  • High CTDNEP1 expression was associated with poorer prognosis in KIRC/ccRCC, with a notable Stage III association.
  • Prognostic associations in KIRP/papillary RCC were limited and inconsistent.
  • The prognostic findings are observational, in-silico associations from public retrospective datasets and do not establish causality.
  • The paper profile notes lack of external/prospective validation and the need for further experimental and clinical validation.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in silico

1Lead resultin silicoTest whether CTDNEP1 expression is prognostic in KIRC and KIRP (survival association; subtype- and stage-dependent patterns).TCGA secondary in-silico prognostic analysisExpand

In plain English

Analysis of TCGA and Pan-Cancer Atlas data using Kaplan–Meier and Cox proportional hazards models found that CTDNEP1 expression is elevated in KIRC and KIRP versus normal tissue (particularly in early-stage tumors). High CTDNEP1 expression was associated with worse patient prognosis in KIRC, with a notable effect reported for Stage III; prognostic associations in KIRP were limited and inconsistent. Analyses were in-silico and associative (secondary analysis of TCGA clinical/outcome data).

Key findings

  • CTDNEP1 expression is higher in KIRC and KIRP tumor tissues than in normal kidney tissues, especially in early-stage tumors.
  • In KIRC, higher CTDNEP1 expression is associated with poorer patient prognosis; association was particularly noted in Stage III.
“Kaplan-Meier survival and Cox proportional hazard analyses were performed to evaluate the association between CTDNEP1 expression and patient prognosis.”
What this piece can’t prove
  • Analyses are secondary, in-silico analyses of TCGA/Pan-Cancer Atlas data; potential for unmeasured confounding and cohort-specific biases.
  • Abstract lacks reporting of key statistical details (hazard ratios, p-values, confidence intervals, sample sizes, number of events), limiting assessment of effect magnitude and precision.
  • Prognostic associations are observational and do not demonstrate causality.
  • Stage- and subtype-specific findings (e.g., Stage III emphasis in KIRC) are reported qualitatively without detailed metrics or external validation.

1 further detail could not be confirmed from the summary.

2in silicoCharacterize CTDNEP1 expression differences between RCC subtypes (KIRC, KIRP) and normal tissue using TCGA/Pan-Cancer data, including stage-related patterns.TCGA/Pan-Cancer in-silico expression comparisonExpand

In plain English

Using TCGA and Pan-Cancer Atlas expression data, the authors report that CTDNEP1 mRNA levels are higher in kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP) tumor samples compared with normal tissue, with the increased expression particularly evident in early-stage tumors.

Key findings

  • CTDNEP1 expression is higher in KIRC tumors compared with normal kidney tissue (reported as significant).
  • CTDNEP1 expression is higher in KIRP tumors compared with normal kidney tissue (reported as significant).
“We analyzed CTDNEP1 expression in KIRC and KIRP using TCGA and Pan-Cancer Atlas datasets.”
What this piece can’t prove
  • Findings are based on retrospective analyses of public TCGA/Pan-Cancer datasets; abstract provides no independent validation cohort.
  • Abstract does not report key analytic details (normalization, covariate adjustment, exact statistical tests, sample sizes per group), limiting assessment of robustness.
  • Observational in-silico expression comparisons cannot determine causality or mechanistic contribution of CTDNEP1 to tumor development.
3in silicoIdentify biological processes/pathways associated with CTDNEP1 expression in KIRC and KIRP via functional enrichment analyses (GO/KEGG).In-silico GO/KEGG enrichment of CTDNEP1-associated gene setsExpand

In plain English

The study performed GO and KEGG pathway enrichment on gene sets associated with CTDNEP1 expression in TCGA KIRC and KIRP cohorts and reports subtype-specific pathway associations: immune-related pathways in KIRC and PI3K-Akt, MAPK, and TGF-β signaling pathways in KIRP. The abstract does not report specific enriched terms, statistical thresholds, or gene-selection details.

Key findings

  • In KIRC, functional enrichment analysis revealed associations with immune-related pathways.
  • In KIRP, enrichment analysis indicated associations with pathways involved in PI3K-Akt, MAPK, and TGF-β signaling.
“We explored biological processes associated with CTDNEP1 expression using GO and KEGG pathway enrichment analyses.”
What this piece can’t prove
  • No specific enriched GO/KEGG term names, p-values, gene counts, or effect sizes are provided.
  • Enrichment results are associative and derived from in-silico analysis of bulk TCGA transcriptomes; causal contribution of CTDNEP1 to the reported pathways is not demonstrated and requires experimental validation.

1 further detail could not be confirmed from the summary.

4in silicoAssess association between CTDNEP1 expression and the tumor immune microenvironment via immune infiltration correlation analysis.in silicoExpand

In plain English

Using TCGA bulk-expression data, the authors performed immune infiltration inference and correlation analysis and reported that CTDNEP1 expression showed only weak correlation with immune cell infiltration in RCC (KIRC/KIRP).

Key findings

  • CTDNEP1 expression showed only weak correlation with immune cell infiltration in the immune infiltration analysis.
“Finally, we examined the relationship between CTDNEP1 expression and the tumor immune microenvironment using immune infiltration analysis.”
What this piece can’t prove
  • Abstract lacks methodological detail for the immune infiltration inference (tool, signatures, or parameters not reported).

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 34 candidate papers

And 28 more candidates considered.